Combining the VEGF antagonist bevacizumab with olaparib or niraparib improved the median progression free survival (PFS) in newly diagnosed and recurrent ovarian cancer patients, in both HRD and HR-proficient cohorts [54]. Here, VEGFA is linked to ovarian carcinoma.